Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
about
Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysisAn update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humansPrevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonComparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients.Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone.Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients.Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.Safety of neurokinin-1 receptor antagonists.Anticipatory nausea in animal models: a review of potential novel therapeutic treatments.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Update on the management of chemotherapy-induced nausea and vomiting - focus on palonosetron.Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting.
P2860
Q26997344-6B842343-CB83-4C2C-AD9D-B3AE94013B51Q34588516-EAE94FE5-0D50-45FA-88FA-98677A6ED524Q35662036-5046D555-C025-43F2-BA84-648379018B26Q35970506-219B089B-D1A4-4EDB-8108-6FD9CCA5100FQ36093627-D9DB1AC0-019E-4633-A137-4E77F9F3C37BQ36220364-372B1C27-A9EF-4B8A-981C-9814BFA880B8Q36285281-C267C0C9-DDCB-4C30-A8B5-E657EA319A72Q36371595-C7E40D1F-533F-497B-A4DF-EA2689CE4C25Q36510947-761C38F9-5FA9-4747-99D5-DB6C18EF8825Q37245902-16D2E7BA-AE2C-42CF-AD2B-FEAC9E27AAAEQ37480802-32F61559-CD16-4A29-BB71-68DC0CCCD026Q38109245-3D937B5D-CF39-43CA-961B-450DC6A9FF66Q38208999-1A6FCBEA-F00B-47FA-947E-0B2522E8C162Q38250191-ADDD878B-C3B8-45DE-99FC-9689C588EAC7Q38497106-7B6823EF-9600-4735-9F83-8BA3432B2E45Q38574240-8E57C7C2-0D7C-4677-BFC4-35F7F26046BDQ38892469-4789F382-1196-402C-B770-8D5518EFCD03Q39359365-0E35EE6D-BF9B-4D78-95F8-8C56C70AD34DQ47641840-01141D56-6427-4AC7-926C-6B11F6071FCDQ48076549-EA704F1A-9818-43BB-A24C-2D15F855934AQ50441498-42AD6D0B-B804-40A1-B7AD-56856FF3AD27Q50442516-A3EC4FB9-C743-445F-A803-5631D3F48A88Q52632403-979F39A7-151D-46DD-AF66-06EB5583ECF0
P2860
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@en
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@nl
type
label
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@en
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@nl
prefLabel
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@en
Palonosetron plus 3-day aprepi ...... ighly emetogenic chemotherapy.
@nl
P2093
P2860
P50
P1476
Palonosetron plus 3-day aprepi ...... highly emetogenic chemotherapy
@en
P2093
Barbara Cimadon
Bruno Gori
Cristina De Luca
Enrico Cortesi
Ester Del Signore
Flavia Longo
Giovanni Mansueto
I D'Antoni
Marisa Di Seri
Roberta Grande
P2860
P2888
P304
P356
10.1007/S00520-010-0930-X
P577
2010-06-16T00:00:00Z
P6179
1031070466